Valuation Alnylam Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 10/04/2026 BST			5-day change	1st Jan Change
322.11 ^USD	+0.26%		+1.02%	-19.00%

04-06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
03-30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Capitalization ¹	20,282	29,238	24,021	30,350	52,535	42,719	-	-
Change	-	44.16%	-17.84%	26.35%	73.09%	-18.68%	-	-
Enterprise Value (EV) ¹	18,522	28,132	23,979	30,128	52,325	39,450	36,333	33,528
Change	-	51.88%	-14.76%	25.64%	73.67%	-24.61%	-7.9%	-7.72%
P/E ratio	-23.6x	-25.6x	-54.4x	-108x	171x	49.1x	30.1x	23.9x
PBR	34.6x	-186x	-109x	453x	66.7x	19.1x	9.66x	5.87x
PEG	-	-0.9x	0.9x	2.8x	-1x	0x	0.5x	0.9x
Capitalization / Revenue	24x	28.2x	13.1x	13.5x	14.1x	7.67x	5.9x	4.98x
EV / Revenue	21.9x	27.1x	13.1x	13.4x	14.1x	7.08x	5.02x	3.91x
EV / EBITDA	-28x	-38x	-105x	-251x	93.9x	33.8x	20.1x	15.2x
EV / EBIT	-26.1x	-35.8x	-85x	-170x	104x	35.8x	19.8x	14.6x
EV / FCF	-25.8x	-45.9x	572x	-707x	112x	29.1x	18.4x	13.6x
FCF Yield	-3.88%	-2.18%	0.17%	-0.14%	0.89%	3.44%	5.44%	7.35%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-7.2	-9.3	-3.52	-2.18	2.33	6.558	10.69	13.46
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	844.3	1,037	1,828	2,248	3,714	5,569	7,240	8,585
EBITDA ¹	-661.1	-740.6	-228.1	-120.2	557.2	1,166	1,811	2,211
EBIT ¹	-708.7	-785.1	-282.2	-176.9	501.6	1,103	1,832	2,290
Net income ¹	-852.8	-1,131	-440.2	-278.2	313.7	918	1,497	1,915
Net Debt ¹	-1,760	-1,105	-41.37	-222.5	-210.3	-3,269	-6,387	-9,191
Reference price ²	169.58	237.65	191.41	235.31	397.65	322.11	322.11	322.11
Nbr of stocks (in thousands)	119,601	123,028	125,493	128,981	132,114	132,623	-	-
Announcement Date	10/02/22	23/02/23	15/02/24	13/02/25	12/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ALNYLAM PHARMACEUTICALS, INC.	49.12x	7.08x	33.84x	-.--%	42.72B
ELI LILLY AND COMPANY	27.6x	10.48x	21x	0.71%	841B
JOHNSON & JOHNSON	25.27x	5.88x	15.98x	2.22%	574B
ABBVIE INC.	23.1x	6.26x	12.64x	3.33%	368B
ASTRAZENECA PLC	25.82x	5.33x	14.9x	1.62%	318B
MERCK & CO., INC.	28.22x	5.02x	15.65x	2.78%	300B
NOVARTIS AG	21.36x	5.74x	13.88x	2.86%	295B
AMGEN INC.	23.42x	6.07x	10.8x	2.86%	189B
GILEAD SCIENCES, INC.	19.15x	5.87x	10.62x	2.34%	173B
Average	27.01x	6.41x	16.59x	2.08%	344.48B
Weighted average by Cap.	25.49x	7.05x	16.24x	2.01%